TY  - JOUR
AU  - Holländer, B.
AU  - Buca, D.
AU  - Mantl, S.
AU  - Hartmann, J.M.
TI  - Wet Chemical Etching of Si, Si1-xGex, and Ge in HF:H2O2:CH3COOH
JO  - Journal of the Electrochemical Society
VL  - 157
SN  - 0013-4651
CY  - Pennington, NJ
PB  - Electrochemical Society
M1  - PreJuSER-9643
SP  - H643 - H646
PY  - 2010
N1  - This work was supported by the European Commission, Information Society Technology (IST), within the framework of PULLNANO, contract no. IST-026828.
AB  - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000277260200080
DO  - DOI:10.1149/1.3382944
UR  - https://juser.fz-juelich.de/record/9643
ER  -